Chronic Lymphocytic Leukemia | Specialty

Dr. Jan A. Burger on Role of MRD-Negativity in CLL

October 15th 2016

Jan A. Burger, MD, PhD, associate professor, department of leukemia, division of cancer medicine, The University of Texas MD Anderson Cancer Center, discusses the role of minimal residual disease (MRD)-negativity in chronic lymphocytic leukemia (CLL).

Venetoclax Receives Positive CHMP Opinion for CLL

October 15th 2016

The Committee for Medicinal Products for Human Use has recommended approval of venetoclax for the treatment of patients with chronic lymphocytic leukemia who have a 17p deletion (del[17p]) or TP53 mutation and are not good candidates for or have failed on a B-cell receptor pathway inhibitor. The potential indication would also be for patients who do not harbor the deletion or mutation but have progressed on both a BCR inhibitor and chemoimmunotherapy.

Dr. William Wierda on Role for Ibrutinib in Frontline CLL

October 3rd 2016

William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discuses which chronic lymphocytic leukemia patients may benefit from ibrutinib frontline therapy and questions that remain after the RESONATE-2 trial.

Ibrutinib or FCR: Wierda Discusses First-Line Options for CLL

October 2nd 2016

There has been some debate over what should be the standard frontline treatment for patients with chronic lymphocytic leukemia: ibrutinib or chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab.

Dr. Steven Coutre on Frontline Treatment Decisions in CLL

October 2nd 2016

​Steven Coutre, MD, professor of medicine (hematology) at Stanford University Medical Center, discusses considerations when selecting between oral therapies like ibrutinib and chemoimmunotherapy for first-line treatment of chronic lymphocytic leukemia (CLL).

Dr. Constantine S. Tam on BCL2 Inhibitors Compared to Ibrutinib, Idelalisib

September 29th 2016

Constantine S. Tam, MD, Consultant Hematologist, Division of Hematology and Oncology, Peter MacCallum Cancer Center, Melbourne, Australia discusses BCL2 inhibitors in chronic lymphocytic leukemia (CLL).

Recent Success in CLL Spurs Development of New Agents

September 13th 2016

Recent success with novel agents for chronic lymphocytic leukemia has spurred development of more agents in the same therapeutic classes; however, definitive advantages over the originals have yet to be established.

Venetoclax/Rituximab Combo Active in CLL

September 10th 2016

Combining the BCL-2 inhibitor venetoclax (Venclexta) with the anti-CD20 agent rituximab (Rituxan) led to objective responses in 86% of patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL

September 6th 2016

Jennifer Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the lessons oncologists have learned from the RESONATE-2 trial, which showed a benefit with ibrutinib (Imbruvica) over chlorambucil in patients with chronic lymphocytic leukemia (CLL).

Cheson Highlights Choices in Frontline CLL Care

September 1st 2016

Bruce Cheson, MD, discusses how frontline treatment for chronic lymphocytic leukemia has evolved well beyond a "one-size-fits-all" approach, with patient and disease characteristics and physician/patient discussions determining the optimal therapeutic approach.

FDA Approves Ofatumumab Combination for Relapsed CLL

August 31st 2016

The FDA has approved ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for patients with relapsed chronic lymphocytic leukemia.

Expert Discusses Optimal Care for Relapsed/Refractory CLL

August 29th 2016

Jennifer Woyach, MD, discussed using the FDA-approved agents ibrutinib (Imbruvica), idelalisib (Zydelig), and venetoclax (Venclexta) in a hypothetical patient scenario, and highlighted emerging targets and treatments in relapsed/refractory chronic lymphocytic leukemia.

Dr. Mato on Managing Side Effects With Ibrutinib/Idelalisib in CLL

August 24th 2016

Anthony Mato, MD, director of the Chronic Lymphocytic Leukemia Program, University of Pennsylvania, discusses how oncologists can manage adverse events associated with ibrutinib (Imbruvica) and idelalisib (Zydelig) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Kay on Genetic Investigations in Chronic Lymphocytic Leukemia

August 18th 2016

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the genetic investigations being conducted in chronic lymphocytic leukemia (CLL), and more specifically, monoclonal b-cell lymphocytosis, which resembles CLL but does not meet the same criteria.

Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL

August 16th 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

August 12th 2016

Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

August 11th 2016

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. John Byrd on Ibrutinib in CLL

August 9th 2016

Novel Treatment Strategies Emerging for CLL

July 27th 2016

Ibrutinib (Imbruvica) and idelalisib (Zydelig) have become standard of care treatments for patients with relapsed or high-risk chronic lymphocytic leukemia, with ongoing studies in progress to move ibrutinib into the frontline setting.

CAR T-Cell Therapy CTL019 Shows Promise in Phase II CLL Trial

July 22nd 2016

The CD19-targeting CAR T-cell therapy CTL019 induced responses in 53% of patients with relapsed/refractory chronic lymphocytic leukemia, including complete remissions in 35% of patients.